These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16511643)

  • 21. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 22. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.
    De Stefano N; Curtin F; Stubinski B; Blevins G; Drulovic J; Issard D; Shotekov P; Gasperini C;
    Mult Scler; 2010 Jul; 16(7):888-92. PubMed ID: 20200197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ulnar nerve injuries of the hand producing intrinsic muscle denervation on magnetic resonance imaging.
    Barberie JE; Connell DG; Munk PL; Janzen DL
    Australas Radiol; 1999 Aug; 43(3):355-7. PubMed ID: 10901935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apparent weakness of ulnar-innervated muscles in radial palsy.
    Sadeh M; Gilad R; Dabby R; Blumen SC
    Neurology; 2004 Apr; 62(8):1424-5. PubMed ID: 15111689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    Buttari F; Zagaglia S; Marciano L; Albanese M; Landi D; Nicoletti CG; Mercuri NB; Silvestrini M; Provinciali L; Marfia GA; Mori F; Centonze D
    J Neuroimmunol; 2017 Apr; 305():172-174. PubMed ID: 28284340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Assessing weakness in patients with ulnar neuropathy: comparison between a custom hand muscle dynamometer and a pinch dynamometer.
    Buschbacher R
    Am J Phys Med Rehabil; 2012 Mar; 91(3):284. PubMed ID: 22317942
    [No Abstract]   [Full Text] [Related]  

  • 28. Ipsilateral silent period: a marker of callosal conduction abnormality in early relapsing-remitting multiple sclerosis?
    Jung P; Beyerle A; Humpich M; Neumann-Haefelin T; Lanfermann H; Ziemann U
    J Neurol Sci; 2006 Dec; 250(1-2):133-9. PubMed ID: 17011585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of segmental nerve conduction studies in ulnar mononeuropathy at the elbow.
    Azrieli Y; Weimer L; Lovelace R; Gooch C
    Muscle Nerve; 2003 Jan; 27(1):46-50. PubMed ID: 12508294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
    Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
    Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of hand diagrams in screening for ulnar neuropathy: comparison with electrodiagnostic studies.
    Werner RA; Chiodo T; Spiegelberg T; Franzblau A
    Muscle Nerve; 2012 Dec; 46(6):891-4. PubMed ID: 23042421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-segment nerve conduction studies in the localization of ulnar neuropathy of the elbow: use of flexor carpi ulnaris recordings.
    Lo YL; Leoh TH; Xu LQ; Nurjannah S; Dan YF
    Muscle Nerve; 2005 May; 31(5):633-6. PubMed ID: 15645413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of demyelinating ulnar nerve injury on strength and fatigue.
    Allen MD; Doherty TJ
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):38-45. PubMed ID: 22361624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
    Koch-Henriksen N; Sørensen PS
    Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
    J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.